Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Decreases By 40.9%

Posted by James Quigley on Mar 29th, 2025

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 70,800 shares, a decline of 40.9% from the February 28th total of 119,700 shares. Approximately 3.9% of the company’s stock are short sold. Based on an average daily volume of 1,850,000 shares, the days-to-cover ratio is presently 0.0 days.

Cyclerion Therapeutics Stock Down 1.5 %

CYCN stock traded down $0.04 during trading on Friday, reaching $2.57. The stock had a trading volume of 12,682 shares, compared to its average volume of 1,321,396. Cyclerion Therapeutics has a one year low of $1.27 and a one year high of $9.47. The company’s 50 day moving average is $2.95 and its two-hundred day moving average is $2.89. The company has a market capitalization of $6.96 million, a price-to-earnings ratio of -2.11 and a beta of 2.09.

Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.22 EPS for the quarter. The business had revenue of $1.81 million for the quarter.

Institutional Investors Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Renaissance Technologies LLC purchased a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned approximately 0.39% of Cyclerion Therapeutics as of its most recent filing with the Securities & Exchange Commission. 75.62% of the stock is owned by institutional investors and hedge funds.

Cyclerion Therapeutics Company Profile

(Get Free Report)

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.